Lck Antibody (0.T.84): sc-71498
- Lck Antibody (0.T.84) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- epitope mapping between amino acids 54-222 of mouse Lck p56
- recommended for detection of Lck p56 of mouse, rat and human origin by WB, IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- See Lck (3A5): sc-433 for Lck antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG2b BP-HRP is the preferred secondary detection reagent for Lck Antibody (0.T.84) for WB applications. This reagent is now offered in a bundle with Lck Antibody (0.T.84) (see ordering information below).
QUICK LINKS
SEE ALSO...
Lck Antibody (0.T.84) is a mouse monoclonal IgG2b light chain antibody that detects Lck in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Lck is a crucial member of the Src family of non-receptor tyrosine kinases, which play a significant role in T cell signaling and immune response regulation. Located primarily in the plasma membrane and cytoplasm of T cells, Lck is essential for the initiation of T cell receptor (TCR) signaling, which is vital for T cell activation, proliferation, and differentiation. The proper localization of Lck ensures optimal interaction with other signaling molecules upon TCR engagement, facilitating downstream signaling cascades that lead to effective immune responses. Dysregulation of Lck activity or localization can result in impaired immune function or contribute to autoimmune diseases, highlighting the importance of Lck in maintaining immune homeostasis. Anti-Lck antibody (0.T.84) serves as an invaluable tool for researchers studying T cell biology and the mechanisms underlying immune responses.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Lck Antibody (0.T.84) References:
- The role of competing mechanisms on Lck regulation. | Bozso, SJ., et al. 2020. Immunol Res. 68: 289-295. PMID: 32794043
- Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. | Laukkanen, S., et al. 2022. Blood. 140: 1891-1906. PMID: 35544598
- Unique roles of co-receptor-bound LCK in helper and cytotoxic T cells. | Horkova, V., et al. 2023. Nat Immunol. 24: 174-185. PMID: 36564464
- New insights into the Lck-NF-κB signaling pathway. | Zhang, J., et al. 2023. Front Cell Dev Biol. 11: 1120747. PMID: 36910149
- A Novel Biallelic LCK Variant Resulting in Profound T-Cell Immune Deficiency and Review of the Literature. | Lanz, AL., et al. 2023. J Clin Immunol. 44: 1. PMID: 38100037
- Combined Immunodeficiency Caused by a Novel Nonsense Mutation in LCK. | Keller, B., et al. 2023. J Clin Immunol. 44: 4. PMID: 38112969
- The phosphatase DUSP22 inhibits UBR2-mediated K63-ubiquitination and activation of Lck downstream of TCR signalling. | Shih, YC., et al. 2024. Nat Commun. 15: 532. PMID: 38225265
- CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis. | Acharya, S., et al. 2024. Cancer Discov. 14: 1879-1900. PMID: 38900051
- Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event. | De Sanctis, JB., et al. 2024. Cancers (Basel). 16: PMID: 39123358
- c-CBL/LCK/c-JUN/ETS1/CD28 axis restrains childhood asthma by suppressing Th2 differentiation. | Yang, N. and Wang, T. 2024. Mol Med. 30: 164. PMID: 39342146
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lck Antibody (0.T.84) | sc-71498 | 200 µg/ml | $322.00 | |||
Lck Antibody (0.T.84): m-IgG2b BP-HRP Bundle | sc-548452 | 200 µg Ab; 10 µg BP | $361.00 | |||
Lck Antibody (0.T.84) FITC | sc-71498 FITC | 200 µg/ml | $336.00 | |||
Lck Antibody (0.T.84) PE | sc-71498 PE | 200 µg/ml | $349.00 |